Press Releases.

-Late-breaking data featured in oral presentation; three additional posters examining RG-101 pharmacokinetics, preclinical results to be presented-

-Regulus Earns $2.5 Million Milestone Payment from AstraZeneca-

- Achieved Key 2014 'Clinical Map Initiative' Goals to Advance microRNA Therapeutics Pipeline -

-Extended Follow-Up Shows 4/14 Patients Treated with a Single SC Dose of 2 mg/kg of RG-101 are Target Not Detected at Day 85 -

Accelerates RG-101 for HCV with Dual-Track Clinical Development Strategy; Top-Line, Single Dose, 4 mg/kg Results as Well as 2mg/kg Extended Follow Up Results from Ongoing Study to be Reported in Early February 2015

- Treatment with RG-012 Protects Kidney Function and Demonstrates Additive Therapeutic Effect with Emerging Standard of Care in Preclinical Model of Alport Syndrome -

- Demonstrated Human Proof-of-Concept; 'Clinical Map Initiative' Updated -

- Interim Results from Ongoing Study Demonstrate Human Proof-of-Concept and Underscore the Value of Regulus' microRNA Platform -

-New Preclinical Results Increase Mechanistic Understanding of Targeting miR-103/107 for Metabolic Disorders and miR-21 for Renal Dysfunction in Alport Syndrome Patients-

-Newly Allowed Claims Demonstrate Regulus' Leadership in the microRNA Field-

-ATHENA to Shed Light on Rare, Life-Threatening Kidney Disease -

- 'Clinical Map Initiative' On Track; Human Proof of Concept Results for RG-101 and Nomination of Third Clinical Candidate Expected by YE 2014 -

- New Method of Use Claims Strengthen Patent Estate Covering microRNA-122 Inhibitors for the Treatment of HCV Infection -

- Recognized Industry Leader Brings Extensive Clinical and Product Development Expertise -

- 'Clinical Map Initiative' On Track; Advanced RG-101 and RG-012, Expect to Nominate Third microRNA Clinical Candidate by YE 2014 -

- Data Advances microRNA Oncology Portfolio -

- Study Designed to Demonstrate Human Proof-of-Concept Results by YE 2014 -

- Achieved All Goals on 'Road to the Clinic'; Launched 'Clinical Map Initiative'-

-RG-012 is an anti-miR Targeting microRNA-21 for the Treatment of Alport Syndrome, a Life-Threatening, Genetic Kidney Disease with No Approved Therapy-

-Martin Beaulieu, Ph.D. Brings Extensive Diagnostic Assay Development Experience-

-Regulus to Develop microRNA-21 for Alport Syndrome, a Life-Threatening Orphan Kidney Disease, and microRNA-21 in Oncology, to Human Proof-of-Concept-

-Mr. Szekeres Brings Extensive Strategic and Transactional Deal Experience-

-Regulus microMarkers™ Designed to Support Regulus' Therapeutic Pipeline, its Collaborators and Strategic Partners-

- Regulatory Application for RG-101 to be Filed in the Near Term: Clinical Studies in Man Expected to Commence in Early 2014 -

- New Survival Data Presented at Kidney Week 2013 -

- Late-Breaking Poster to be Presented at AASLD -

-'Road to the Clinic' Strategy On Track; Preparing for Clinical Development of RG-101 for HCV; Second microRNA Clinical Candidate to be Nominated by Year End -

Include multimedia assets in your release for better visibility

- Nominated RG-101 in HCV as First microRNA Candidate for Clinical Development-

Industry Legend Brings Deep Biotechnology Expertise

-Progressed Partnered and Proprietary microRNA Programs-

Mr. Foletta Brings Extensive Financial and Commercial Biotechnology Expertise

-Formed Multiple Strategic Relationships to Support our microRNA-based Therapeutics and Biomarker Platforms-

Stanley T. Crooke, M.D., Ph.D. and Barry E. Greene to Step Down

-Regulus, in partnership with Sanofi, is developing novel anti-fibrotic therapies targeting microRNAs-

- Initial focus on discovery of microRNAs as biomarkers for multiple sclerosis (MS) -

Focused on three exclusive microRNA targets

- Japan Patent Office Joins Australian, European and U.S. Patent Offices in Granting Claims for Therapeutic Use of Inhibiting microRNA-122 for HCV Treatment

-New study published in Science Translational Medicine demonstrates microRNA-21 contributes to fibrogenesis in the kidney

-New Pre-clinical Data to be Presented on Proprietary Therapeutic Programs in Metabolic Disease and Cancer at Keystone Symposium and AACR Special Conference

-Regulus, Accelerate Brain Cancer Cure (ABC2) and Samsung Medical Center to Advance microRNA Therapeutics for Glioblastoma -

-Regulus Scientists to Provide Update on Lead Therapeutic Program at American Society of Nephrology Meeting-

-The Australia Patent Office Joins the U.S. and European Patent Offices in Granting Claims for Inhibiting microRNA-122 to Reduce Viral Load-

Speakers to Include NYU Langone Medical Center's Kathryn Moore, Ph.D., Who will Cover Research Findings Published Last Week in Nature

Speakers to Include NYU Langone Medical Center's Kathryn Moore, Ph.D., Who will Cover Research Findings Published Last Week in Nature

- New publication in Nature shows therapeutic silencing of microRNA-33a/b for atherosclerosis -

-Regulus Chief Scientific Officer to Provide Updates on Lead Therapeutic Programs Targeting microRNA-33 and microRNA-21 at Oligonucleotide Therapeutics Society Meeting-

- Professor and Howard Hughes Medical Institute Investigator at Cold Spring Harbor Laboratory known for the molecular elucidation of small regulatory RNAs -

- Work of scientists with Regulus, Alnylam and ETH Zurich shows microRNAs 103/107 are upregulated in mouse models of obesity; targeting with anti-miRs improves glucose homeostasis and insulin sensitivity -

- Paper published in Journal of Clinical Investigation supports development of anti-microRNA 33 as potential therapeutic for atherosclerosis and related metabolic diseases -